Keith Alexander

Keith Alexander, listed as finance chief, has filed trades across 2 companies (mainly through Finansinspektionen), most often in ExpreS2ion Biotech Holding AB and ExpreS2ion Biotech Holding AB (EXPRS2). The record holds 8 filings, for trades running from 15 October 2020 to 1 July 2026.

The open-market record is one-sided, with 4 purchases worth €6,877 and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 2 share grants. So far in 2026, the count stands at 1 purchase and no sales.

The median purchase comes to €964.

The record was last updated on 1 July 2026 with a share grant in ExpreS2ion Biotech Holding AB. The last insider purchase was made public on 1 May 2026, 191 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, MAR article 19 gives managers three business days to notify a trade. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.